Imprecise information on significance of gene variants diminishes value of genetic panel testing
the ONA take:
Advances in technology provide people with the option of undergoing multigene testing, or panel testing, to determine their risk for developing various cancers.
However, an international consortium of authors caution clinicians about using these tests. Although the tests are helpful in identifying genetic mutations with the potential to increase a woman’s risk for breast and other cancers, clinicians need to be aware of, and share with patients, the limitations of test results.
Panel testing covers more than 100 genes, 21 of which are associated with breast cancer. Information about many genetic variants is lacking, and positive results may cause undue stress and anxiety over benign conditions.
In addition, patients may take significant or unnecessary risk-reducing interventions or screenings based on limited information.
The authors acknowledge that there is a significant body of evidence to support clinical action when some genetic variants are identified, such as BRCA1 and BRCA2 gene mutations; however, the implications of many other mutations are too imprecise and require further investigation.
They recommend that patients should be informed of the potential for uncertainty regarding the results.
Advances in technology provide people with the option of undergoing multigene testing determine their risk for developing cancer.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Breast Cancer Screening Recommendations Not Completely Reflective of Race, Age
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|